Last reviewed · How we verify
Placebo to indacaterol
Placebo to indacaterol is a Small molecule drug developed by Novartis. It is currently FDA-approved for Used as control arm in clinical trials comparing indacaterol efficacy and safety.
Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials.
Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials. Used for Used as control arm in clinical trials comparing indacaterol efficacy and safety.
At a glance
| Generic name | Placebo to indacaterol |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used in randomized controlled trials to establish the baseline effect of disease natural history, standard care, and patient expectation. It allows researchers to isolate the true therapeutic effect of the active drug (indacaterol in this case) by comparison. Placebo responses can be substantial due to psychological and physiological factors.
Approved indications
- Used as control arm in clinical trials comparing indacaterol efficacy and safety
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD (PHASE1, PHASE2)
- U-LABA/ICS Effects on Exercise Performance, Indacaterol (NA)
- A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD (PHASE2)
- 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (PHASE3)
- QVA Mechanistic Efficacy Study (Receptor Effects, Etc) (PHASE4)
- Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to indacaterol CI brief — competitive landscape report
- Placebo to indacaterol updates RSS · CI watch RSS
- Novartis portfolio CI